Trials / Unknown
UnknownNCT03880695
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma
Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma : a One-arm, Multi-center, Prospective Clinical Trial (ALTER-S001)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The investigators explored the activity of anlotinib combined with Liposomal Doxorubicin in patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib+ Liposomal Doxorubicin | Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2021-04-01
- Completion
- 2021-05-01
- First posted
- 2019-03-19
- Last updated
- 2019-03-21
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03880695. Inclusion in this directory is not an endorsement.